TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Salpingectomy (Tubectomy) With Delayed Oophorectomy to Improve Quality of Life as Alternative for Risk Reducing Salpingo-oophorectomy in BRCA1/2 Gene Mutation Carriers
Brief Summary: The purpose of this study is to determine whether an innovative preventive strategy, consisting of early salpingectomy upon completion of childbearing with delayed oophorectomy beyond current guideline age, improves menopause-related quality of life without significantly increasing ovarian cancer incidence in comparison to current standard salpingo-oophorectomy in female BRCA1/2 mutation carriers.


Options:
A: Arm Label: Salpingectomy with delayed oophorectomy; Type: EXPERIMENTAL; Interventions: Procedure: Salpingectomy with delayed oophorectomy | Arm Label: Risk-reducing salpingo-oophorectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Risk-reducing salpingo-oophorectomy | Intervention Type: PROCEDURE; Name: Salpingectomy with delayed oophorectomy; Assigned to Arm(s): Salpingectomy with delayed oophorectomy | Intervention Type: PROCEDURE; Name: Risk-reducing salpingo-oophorectomy; Assigned to Arm(s): Risk-reducing salpingo-oophorectomy
B: Arm Label: Salpingectomy group; Type: EXPERIMENTAL; Interventions: Procedure: Salpingectomy | Arm Label: No Salpingectomy Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Salpingectomy; Assigned to Arm(s): Salpingectomy group
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Iltamiocel; Type: EXPERIMENTAL; Interventions: Biological: Iltamiocel | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: Iltamiocel; Assigned to Arm(s): Iltamiocel
D: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Device: Eclipse™ System | Intervention Type: DEVICE; Name: Eclipse™ System; Assigned to Arm(s): Treatment

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Protocol of a Randomised Clinical Trial in Colorectal Cancer Patients
Brief Summary: The purpose of the study is to determine whether a quality of life pathway with defined diagnostic and therapeutic options improves quality of life in colorectal cancer patients during follow-up.


Options:
A: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group
B: Arm Label: Prehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prehabilitation | Arm Label: No-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): Prehabilitation
C: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Standard nutrition counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Prehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Arm Label: Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Intervention Type: BEHAVIORAL; Name: Physical Exercise Program; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: DIETARY_SUPPLEMENT; Name: Whey Protein Isolate Powder; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: BEHAVIORAL; Name: Relaxation Techniques; Assigned to Arm(s): Prehabilitation, Rehabilitation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Protocol of a Randomised Clinical Trial in Colorectal Cancer Patients
Brief Summary: The purpose of the study is to determine whether a quality of life pathway with defined diagnostic and therapeutic options improves quality of life in colorectal cancer patients during follow-up.


Options:
A: Arm Label: Pre and postoperative exercise; Type: EXPERIMENTAL; Interventions: Other: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Pre and postoperative exercise
B: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Standard nutrition counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
C: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group
D: Arm Label: Exercise Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise Intervention | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise Intervention; Assigned to Arm(s): Exercise Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Protocol of a Randomised Clinical Trial in Colorectal Cancer Patients
Brief Summary: The purpose of the study is to determine whether a quality of life pathway with defined diagnostic and therapeutic options improves quality of life in colorectal cancer patients during follow-up.


Options:
A: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: quality of life pathway | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo control | Intervention Type: BEHAVIORAL; Name: quality of life pathway; Assigned to Arm(s): intervention group | Intervention Type: OTHER; Name: placebo control; Assigned to Arm(s): control group
B: Arm Label: Routine data collection; Type: ACTIVE_COMPARATOR; Interventions: Other: Routine Data collection | Arm Label: Feedback of patient-reported outcomes; Type: EXPERIMENTAL; Interventions: Other: Routine Data collection, Other: Feedback of patient-reported outcomes | Intervention Type: OTHER; Name: Routine Data collection; Assigned to Arm(s): Feedback of patient-reported outcomes, Routine data collection | Intervention Type: OTHER; Name: Feedback of patient-reported outcomes; Assigned to Arm(s): Feedback of patient-reported outcomes
C: Intervention Type: DRUG; Name: Treatment of depression; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Suicide prevention intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Suicide prevention treatment; Assigned to Arm(s): N/A
D: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Loop | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Loop; Assigned to Arm(s): Intervention Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer
Brief Summary: Experimental studies have shown the chemopreventive properties of green tea extract (GTE) on colorectal cancer. And colorectal adenomas are precursors to colorectal cancers. The aim of this study is to determine the preventive effect of GTE supplements on metachronous colorectal adenomas by giving GTE tablets of which are equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day Epigallocatechin gallate (EGCG).


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: GTE group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: GTE (green tea extract) | Intervention Type: DIETARY_SUPPLEMENT; Name: GTE (green tea extract); Assigned to Arm(s): GTE group
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Dietary Supplement: defined green tea catechin extract, Other: laboratory biomarker analysis | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Other: laboratory biomarker analysis | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Arm II | Intervention Type: DIETARY_SUPPLEMENT; Name: defined green tea catechin extract; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: laboratory biomarker analysis; Assigned to Arm(s): Arm I, Arm II
C: Arm Label: Polyphenon E Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyphenon E | Arm Label: Placebo Administration; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E Treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Administration
D: Arm Label: Green tea extract; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Green tea extract of Camellia Sinensis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Green tea extract of Camellia Sinensis followed by placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Green tea extract of Camellia Sinensis; Assigned to Arm(s): Green tea extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Green tea extract of Camellia Sinensis followed by placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pragmatic Randomized Controlled Trial to Evaluate the Impact of HealthPROMISE Platform on Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease
Brief Summary: HealthPROMISE is a mobile application (app) for patients that allows regular tracking of symptoms by patients and communicates them to physicians. The purpose of this randomized controlled trial is to determine the impact of the HealthPROMISE application on improving patient outcomes. The trial will look at how much patients use the application, whether physicians change treatment in response to new information from patients, and how the patients quality of life change over the span of the study. The investigators hypothesize that HealthPROMISE will enhance physician-patient communication and improve clinical outcomes.


Options:
A: Arm Label: HealthPROMISE users; Type: EXPERIMENTAL; Interventions: Other: HealthPROMISE users | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: HealthPROMISE users; Assigned to Arm(s): HealthPROMISE users | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
B: Arm Label: face-to-face consultations; Type: ACTIVE_COMPARATOR; Interventions: Other: face-to-face consultations | Arm Label: telephone consultations; Type: EXPERIMENTAL; Interventions: Other: telephone consultations | Intervention Type: OTHER; Name: telephone consultations; Assigned to Arm(s): telephone consultations | Intervention Type: OTHER; Name: face-to-face consultations; Assigned to Arm(s): face-to-face consultations
C: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: myIBDcoach; Type: EXPERIMENTAL; Interventions: Other: myIBDcoach | Intervention Type: OTHER; Name: myIBDcoach; Assigned to Arm(s): myIBDcoach | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
D: Arm Label: Telemedicine group; Type: EXPERIMENTAL; Interventions: Device: Telemedicine | Arm Label: Telephone support group; Type: EXPERIMENTAL; Interventions: Device: Telephone | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional care | Intervention Type: DEVICE; Name: Telemedicine; Assigned to Arm(s): Telemedicine group | Intervention Type: DEVICE; Name: Telephone; Assigned to Arm(s): Telephone support group | Intervention Type: OTHER; Name: Conventional care; Assigned to Arm(s): Control group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pragmatic Randomized Controlled Trial to Evaluate the Impact of HealthPROMISE Platform on Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease
Brief Summary: HealthPROMISE is a mobile application (app) for patients that allows regular tracking of symptoms by patients and communicates them to physicians. The purpose of this randomized controlled trial is to determine the impact of the HealthPROMISE application on improving patient outcomes. The trial will look at how much patients use the application, whether physicians change treatment in response to new information from patients, and how the patients quality of life change over the span of the study. The investigators hypothesize that HealthPROMISE will enhance physician-patient communication and improve clinical outcomes.


Options:
A: Arm Label: HealthPROMISE users; Type: EXPERIMENTAL; Interventions: Other: HealthPROMISE users | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: HealthPROMISE users; Assigned to Arm(s): HealthPROMISE users | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
B: Arm Label: Educational Video; Type: EXPERIMENTAL; Interventions: Other: Educational video | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational video; Assigned to Arm(s): Educational Video
C: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Weekly Home Monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Arm Label: Home Monitoring Every Other Week; Type: EXPERIMENTAL; Interventions: Behavioral: Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Weekly Home Monitoring | Intervention Type: BEHAVIORAL; Name: Home Monitoring; Assigned to Arm(s): Home Monitoring Every Other Week
D: Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: myIBDcoach; Type: EXPERIMENTAL; Interventions: Other: myIBDcoach | Intervention Type: OTHER; Name: myIBDcoach; Assigned to Arm(s): myIBDcoach | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pragmatic Randomized Controlled Trial to Evaluate the Impact of HealthPROMISE Platform on Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease
Brief Summary: HealthPROMISE is a mobile application (app) for patients that allows regular tracking of symptoms by patients and communicates them to physicians. The purpose of this randomized controlled trial is to determine the impact of the HealthPROMISE application on improving patient outcomes. The trial will look at how much patients use the application, whether physicians change treatment in response to new information from patients, and how the patients quality of life change over the span of the study. The investigators hypothesize that HealthPROMISE will enhance physician-patient communication and improve clinical outcomes.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Loop | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Loop; Assigned to Arm(s): Intervention Group
B: Arm Label: Patient reported safety experiences fed back to PC providers; Type: EXPERIMENTAL; Interventions: Behavioral: Patient reported safety experiences fed back to PC providers | Arm Label: Patient reported safety experiences not fed back to providers; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Patient reported safety experiences fed back to PC providers; Assigned to Arm(s): Patient reported safety experiences fed back to PC providers
C: Arm Label: HealthPROMISE users; Type: EXPERIMENTAL; Interventions: Other: HealthPROMISE users | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: HealthPROMISE users; Assigned to Arm(s): HealthPROMISE users | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control Group
D: Arm Label: Patient Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Patient Decision Aid, Behavioral: Follow-Up Assessments: Questionnaires | Arm Label: Standard Educational Information; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Educational Information, Behavioral: Follow-Up Assessments: Questionnaires | Intervention Type: BEHAVIORAL; Name: Patient Decision Aid; Assigned to Arm(s): Patient Decision Aid | Intervention Type: BEHAVIORAL; Name: Standard Educational Information; Assigned to Arm(s): Standard Educational Information | Intervention Type: BEHAVIORAL; Name: Follow-Up Assessments: Questionnaires; Assigned to Arm(s): Patient Decision Aid, Standard Educational Information

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma.
Brief Summary: The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of benralizumab across the spectrum of asthma disease.


Options:
A: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Arm B; Type: EXPERIMENTAL; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Arm A | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Arm B
D: Arm Label: Reslizumab 110 mg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab, Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication, Drug: Oral Corticosteroid (OCS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication, Drug: Oral Corticosteroid (OCS) | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 110 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Non-Oral Corticosteroid (non-OCS) Asthma Medication; Assigned to Arm(s): Placebo, Reslizumab 110 mg | Intervention Type: DRUG; Name: Oral Corticosteroid (OCS); Assigned to Arm(s): Placebo, Reslizumab 110 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Changes in Cortical Excitability Associated With Upper Limb Motor Recovery - a Study of Neural Strategies Employed in Motor Recovery
Brief Summary: This study is to investigate changes in brain activities in acute stroke patients , and to correlate findings with clinical outcome measures. Another aim of the study is to investigate whether transcranial direct current stimulation (tDCS) could improve motor function in subjects with poor brain activity after stroke. The brain activity will be measured by single and paired pulse TMS (transcranial magnetic stimulation). The study hypothesizes that:

1. The neural mechanisms employed in patients who have different response to TMS stimulation are different. It is hypothesized that patients with no response upon TMS stimulation might have poorer motor function outcome, compared with patients with response upon TMS stimulation.
2. The result of clinical outcome measures is related with TMS measurement.
3. tDCS intervention is beneficial to subjects with poor brain activity. Clinical outcome measures will include a battery of upper limb motor tests such as upper extremity component of the Fugl-Meyer Assessment, Modified Ashworth scale for spasticity, box and block test, and manual muscle testing. Clinical outcome and TMS measurement will be assessed at within 2 weeks, 4-6 weeks and at 6 months post-stroke.


Options:
A: Arm Label: enhanced upper-extremity program, EUEP; Type: EXPERIMENTAL; Interventions: Other: UFT | Arm Label: enhanced lower-extremity program,ELLP); Type: EXPERIMENTAL; Interventions: Other: LFT | Intervention Type: OTHER; Name: UFT; Assigned to Arm(s): enhanced upper-extremity program, EUEP | Intervention Type: OTHER; Name: LFT; Assigned to Arm(s): enhanced lower-extremity program,ELLP)
B: Arm Label: real tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: tDCS | Arm Label: no stimulation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): real tDCS, sham tDCS
C: Arm Label: usual management; Type: OTHER; Interventions: Other: no physical activity | Arm Label: physical training; Type: EXPERIMENTAL; Interventions: Other: physical activity | Intervention Type: OTHER; Name: no physical activity; Assigned to Arm(s): usual management | Intervention Type: OTHER; Name: physical activity; Assigned to Arm(s): physical training
D: Arm Label: Early mobilization; Type: EXPERIMENTAL; Interventions: Other: Early mobilization | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Early mobilization; Assigned to Arm(s): Early mobilization

Answer: B